Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2018 12:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV...
November 29, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Host R&D Day on December 6, 2018

NEW YORK and CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
November 26, 2018 16:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces CEO Transition

NEW YORK and CLEVELAND, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
November 13, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference

NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
November 12, 2018 11:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des dritten Quartals 2018 bekannt

Telefonkonferenz für Anleger am Montag, 12. November, um 10.00 Uhr ET (amerikanische Ostküstenzeit) NEW YORK und CLEVELAND, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:...
November 12, 2018 11:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics annonce ses résultats financiers et les faits marquants du troisième trimestre 2018

Conférence téléphonique est organisée pour les investisseurs le lundi 12 novembre à 10h00 ET (16h00 CET) NEW YORK et CLEVELAND, 12 nov. 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq :...
November 09, 2018 16:20 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights

Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage...
November 06, 2018 11:33 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics und REGENXBIO geben weltweite Exklusivlizenzen für die Behandlung von vier seltenen lysosomalen Speicherkrankheiten mit dem NAV AAV9-Vektor bekannt

Abeona erhält neue Lizenzen für NAV AAV9 zur Entwicklung und Vermarktung von Behandlungen für MPS IIIA, MPS IIIB, INCL und JNCLAbeona zahlt REGENXBIO 20 Millionen US-Dollar im Voraus, 10 Millionen...
November 06, 2018 11:33 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics et REGENXBIO annoncent des licences mondiales exclusives pour le traitement de quatre maladies lysosomiales rares utilisant le vecteur NAV AAV9

Abeona obtient de nouvelles licences pour NAV AAV9, pour le développement et la commercialisation de traitements de MPS IIIA, MPS IIIB et de la maladie de Batten CLN1 et CLN3Abeona s'engage à verser...
November 05, 2018 07:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10...